NCI Launches Preclinical Study on Ivermectin as Potential Cancer Treatment
The National Cancer Institute (NCI), a federal research agency, has initiated a preclinical study on ivermectin as a potential cancer treatment. Anthony Letai, the NCI Director, confirmed the ongoing research, stating that the institute is investigating the drug's properties and its ability to kill cancer cells, citing sufficient reports and interest.
The National Cancer Institute (NCI) has initiated a preclinical study on ivermectin as a potential cancer treatment.
Official Confirmation and Anticipated Results
Director Letai indicated that the results of the ivermectin study are anticipated within a few months. He spoke at a January 30 event, "Reclaiming Science: The People’s NIH," hosted by the MAHA Institute, which aligns with Health and Human Services Secretary Robert F. Kennedy Jr.'s agenda. At the event, NIH Director Jay Bhattacharya emphasized the NIH's responsibility to seriously examine ideas that influence public health.
Ivermectin: Background and Controversy
From Antiparasitic to Unproven Cure
Ivermectin is an antiparasitic drug primarily used for treating infections caused by parasites in humans and animals. During the Covid-19 pandemic, the drug gained increased attention as some groups promoted it as a treatment for Covid-19, despite clinical trials demonstrating its ineffectiveness.
Ivermectin has since become a symbol of resistance for some individuals against established medical practices. Some commentators and online influencers have promoted it as a broad-spectrum cure, including for cancer, without scientific evidence.
Scientific Scrutiny and Prior Findings
Internal Apprehension and Limited Clinical Evidence
Some career scientists within the NCI have expressed apprehension regarding the study, questioning the allocation of research funds given other promising research avenues.
An HHS spokesperson, Emily Hilliard, affirmed the NIH’s commitment to rigorous, gold-standard research.
Previous laboratory research has suggested that ivermectin may have anticancer effects by promoting cell death and inhibiting tumor growth. However, there is currently no evidence demonstrating that ivermectin is safe and effective as a cancer treatment in humans. Preliminary data from a small clinical trial combining ivermectin with immunotherapy for metastatic breast cancer patients did not show significant benefit.
Public Perception and Medical Challenges
Patient Decisions and Health Risks
Physicians report frequent inquiries from cancer patients about ivermectin, often influenced by social media information. There have been instances where patients have reportedly forgone established, effective cancer therapies in favor of ivermectin.
Documented cases also include adolescent patients experiencing ivermectin-related neurotoxicity after self-medicating based on social media posts. Celebrities and online influencers have contributed to the promotion of ivermectin as a potential cancer cure.
Regulatory Status and Political Momentum
FDA Warnings and State Initiatives
The FDA has approved ivermectin for specific uses in humans, such as treating parasitic worms, lice, and rosacea. However, the agency has issued warnings about the dangers associated with large doses.
Political figures, including Robert F. Kennedy Jr., and movements like MAHA, have advanced the view that government and pharmaceutical companies have suppressed inexpensive, off-patent drugs like ivermectin. Some U.S. states have made the drug available over-the-counter, and Florida has announced plans to fund research into ivermectin as a cancer treatment.
NCI's Cautious Outlook
NCI Director Letai cautioned against overly optimistic expectations for ivermectin, stating that "at least on a population level, it's not going to be a cure-all for cancer." The NCI has not specified whether its own scientists are conducting the research or if funding has been directed to an external institution.